Brain 17 Vienna

Chua et al. Clin Lung Cancer 2014

Kouroussis et al. Oncology 2009

WBRT + Temozolomide

WBRT +/- temozolomide

• Patients with NSCLC and > 1 newly

diagnosed brain metastasis

• Poor accrual

• WBRT alone: median OS: 5.7 months

• WBRT + temozolomide: median OS 4.4

Daily low-dose temozolomide:

• Patients with advanced NSCLC; many of them

with brain mets

• “minimal activity as salvage therapy in patients

with advanced NSCLC”